Literature DB >> 28892302

Cancer-Targeted Selenium Nanoparticles Sensitize Cancer Cells to Continuous γ Radiation to Achieve Synergetic Chemo-Radiotherapy.

Leung Chan1, Lizhen He1, Binwei Zhou1, Shouhai Guan2, Mingjun Bo2, Yahui Yang1, Ying Liu3, Xiao Liu3, Yanyang Zhang2, Qiang Xie2, Tianfeng Chen1.   

Abstract

Cancer radiotherapy with 125 I seeds demonstrates higher long-term efficacy and fewer side effects than traditional X-ray radiotherapy owing to its low-dose and continuous radiation but is still limited by radioresistance in clinical applications. Therefore, the design and synthesis of sensitizers that could enhance the sensitivity of cancer cells to 125 I seeds is of great importance for future radiotherapy. Selenium nanoparticles (SeNPs) have been found to exhibit high potential in cancer chemotherapy and as drug carriers. In this study, we found that, based on the Auger-electron effect and Compton effect of Se atoms, cancer-targeted SeNPs in combination with 125 I seeds achieve synergetic effects to inhibit cancer-cell growth and colony formation through the induction of cell apoptosis and cell cycle arrest. Detailed studies on the action mechanisms reveal that the combined treatments effectively activate intracellular reactive oxygen species (ROS) overproduction to regulate p53-mediated DNA damage apoptotic signaling pathways and mitogen-activated protein kinase (MAPK) phosphorylation and to prevent the self-repair of cancer cells simultaneously. Taken together, the combination of SeNPs with 125 I seeds could be further exploited as a safe and effective strategy for next-generation cancer chemo-radiotherapy in clinical applications.
© 2017 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  drug delivery; nanostructures; radiochemistry; selenium; sensitizers

Mesh:

Substances:

Year:  2017        PMID: 28892302     DOI: 10.1002/asia.201701227

Source DB:  PubMed          Journal:  Chem Asian J        ISSN: 1861-471X


  5 in total

1.  Targeted delivery of paclitaxel by functionalized selenium nanoparticles for anticancer therapy through ROS-mediated signaling pathways.

Authors:  Guifang Gong; Bailing Fu; Caixin Ying; Zhiqin Zhu; Xiaoqian He; Yingying Li; Zhuanxing Shen; Qingshan Xuan; Yanqing Huang; Yan Lin; Yinghua Li
Journal:  RSC Adv       Date:  2018-11-30       Impact factor: 4.036

Review 2.  Selenium as a pleiotropic agent for medical discovery and drug delivery.

Authors:  Baozhang Guan; Ruiling Yan; Ruiman Li; Xingwang Zhang
Journal:  Int J Nanomedicine       Date:  2018-11-14

Review 3.  Application of Radiosensitizers in Cancer Radiotherapy.

Authors:  Liuyun Gong; Yujie Zhang; Chengcheng Liu; Mingzhen Zhang; Suxia Han
Journal:  Int J Nanomedicine       Date:  2021-02-12

Review 4.  Nano-selenium and its nanomedicine applications: a critical review.

Authors:  Bozena Hosnedlova; Marta Kepinska; Sylvie Skalickova; Carlos Fernandez; Branislav Ruttkay-Nedecky; Qiuming Peng; Mojmir Baron; Magdalena Melcova; Radka Opatrilova; Jarmila Zidkova; Geir Bjørklund; Jiri Sochor; Rene Kizek
Journal:  Int J Nanomedicine       Date:  2018-04-10

5.  The Antimicrobial, Antioxidant, and Anticancer Activity of Greenly Synthesized Selenium and Zinc Composite Nanoparticles Using Ephedra aphylla Extract.

Authors:  Mustafa Mohsen El-Zayat; Mostafa M Eraqi; Hani Alrefai; Ayman Y El-Khateeb; Marwan A Ibrahim; Hashim M Aljohani; Maher M Aljohani; Moustafa Mohammed Elshaer
Journal:  Biomolecules       Date:  2021-03-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.